Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunovirologic and genetic predictors of post-treatment control after ART interruption in early-treated HIV-1 patients
2024-515419-24-00Phase 4Authorised
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dolutegravir, rilpivirine and dolutegravir + rilpivirine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by IRCCS Ospedale San Raffaele. Planned start Jul 2024; status: authorised.
02
Drugs
dolutegravirrilpivirinedolutegravir + rilpivirine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2024-515419-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515419-24-00.